Fintel reports that on February 9, 2026, Mizuho initiated coverage of Immix Biopharma (NasdaqCM:IMMX) with a Outperform recommendation.
Analyst Price Forecast Suggests 81.60% Upside
As of February 4, 2026, the average one-year price target for Immix Biopharma is $12.24/share. The forecasts range from a low of $12.12 to a high of $12.60. The average price target represents an increase of 81.60% from its latest reported closing price of $6.74 / share.
See our leaderboard of companies with the largest price target upside.
The projected annual revenue for Immix Biopharma is 12MM. The projected annual non-GAAP EPS is -0.87.
What is the Fund Sentiment?
There are 41 funds or institutions reporting positions in Immix Biopharma. This is an increase of 7 owner(s) or 20.59% in the last quarter. Average portfolio weight of all funds dedicated to IMMX is 0.03%, an increase of 23.42%. Total shares owned by institutions increased in the last three months by 37.38% to 3,426K shares. 
The put/call ratio of IMMX is 0.39, indicating a bullish outlook.
What are Other Shareholders Doing?
Blue Owl Capital Holdings holds 986K shares representing 1.87% ownership of the company.
Bleichroeder holds 850K shares representing 1.61% ownership of the company. No change in the last quarter.
VTSMX - Vanguard Total Stock Market Index Fund Investor Shares holds 499K shares representing 0.95% ownership of the company. No change in the last quarter.
VEXMX - Vanguard Extended Market Index Fund Investor Shares holds 199K shares representing 0.38% ownership of the company. No change in the last quarter.
Geode Capital Management holds 187K shares representing 0.36% ownership of the company. In its prior filing, the firm reported owning 161K shares , representing an increase of 14.06%. The firm decreased its portfolio allocation in IMMX by 43.20% over the last quarter.
Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.
Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits.
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
